nach oben

Immunologic Research

Erschienen in:

01.05.2015

Immune protective effect of human alpha-1-antitrypsin gene during β cell transplantation in diabetic mice

verfasst von: Lu Yang, Yu-Ting Liao, Xiao-Fei Yang, Li-Wei Reng, Hui Qi, Fu-Rong Li

Erschienen in: Immunologic Research | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease in which β cells are destroyed. Islet transplantation is the most promising therapeutic treatment for T1D patients. However, allograft rejection and autoimmune reaction have been recognized as primary causes of graft loss after transplantation. Alpha-1-antitrypsin (AAT) is an important serine protease inhibitor in serum. AAT is characterized by anti-inflammation, anti-apoptosis, and induction-specific immunological tolerance. In this study, we successfully established NIT-hAAT cell lines, which are murine islet β cell lines with stable expression of human AAT (hAAT) gene. These NIT-hAAT cells were transplanted under the left kidney capsule of BALB/c diabetic mice. Interestingly, the sustained expression of hAAT in vivo can block the inflammatory cell infiltration and reduce the production of proinflammatory cytokines to effectively prevent nonspecific inflammation. Results showed that hAAT can inhibit the proliferation of lymphocytes, shift the balance between Th17 and Treg, and suppress the maturation of dendritic cells. Therefore, hAAT can serve as a beneficial immunomodulator that limits immune rejection to prolong islet allograft survival and achieve long-term successful transplant outcomes.

Aathira R, Jain V. Advances in management of type 1 diabetes mellitus. World J Diabetes. 2014;5(5):689–96. doi:10.4239/wjd.v5.i5.689.CrossRefPubMedCentralPubMed

Bruni A, Gala-Lopez B, Pepper AR, Abualhassan NS, Shapiro AJ. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab Syndr Obes. 2014;7:211–23. doi:10.2147/DMSO.S50789.PubMedCentralPubMed

Abreu JR, Roep BO. Immune monitoring of islet and pancreas transplant recipients. Curr Diabetes Rep. 2013;13(5):704–12. doi:10.1007/s11892-013-0399-3.CrossRef

Kanak MA, Takita M, Kunnathodi F, Lawrence MC, Levy MF, Naziruddin B. Inflammatory response in islet transplantation. Int J Endocrinol. 2014;2014:451035. doi:10.1155/2014/451035.CrossRefPubMedCentralPubMed

Azzi J, Geara AS, El-Sayegh S, Abdi R. Immunological aspects of pancreatic islet cell transplantation. Expert Rev Clin Immunol. 2010;6(1):111–24.CrossRefPubMed

Loganathan G, Dawra RK, Pugazhenthi S, Wiseman AC, Sanders MA, Saluja AK, et al. Culture of impure human islet fractions in the presence of alpha-1 antitrypsin prevents insulin cleavage and improves islet recovery. Transplant Proc. 2010;42(6):2055–7. doi:10.1016/j.transproceed.2010.05.119.CrossRefPubMedCentralPubMed

Loganathan G, Dawra RK, Pugazhenthi S, Guo Z, Soltani SM, Wiseman A, et al. Insulin degradation by acinar cell proteases creates a dysfunctional environment for human islets before/after transplantation: benefits of alpha-1 antitrypsin treatment. Transplantation. 2011;92(11):1222–30. doi:10.1097/TP.0b013e318237585c.CrossRefPubMedCentralPubMed

Koulmanda M, Bhasin M, Fan Z, Hanidziar D, Goel N, Putheti P, et al. Alpha 1-antitrypsin reduces inflammation and enhances mouse pancreatic islet transplant survival. Proc Natl Acad Sci USA. 2012;109(38):15443–8. doi:10.1073/pnas.1018366109.CrossRefPubMedCentralPubMed

Lewis EC, Shapiro L, Bowers OJ, Dinarello CA. Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci USA. 2005;102(34):12153–8. doi:10.1073/pnas.0505579102.CrossRefPubMedCentralPubMed

10.

Zhang B, Lu Y, Campbell-Thompson M, Spencer T, Wasserfall C, Atkinson M, et al. Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes. 2007;56(5):1316–23. doi:10.2337/db06-1273.CrossRefPubMed

11.

Kalis M, Kumar R, Janciauskiene S, Salehi A, Cilio CM. Alpha 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic beta-cells. Islets. 2010;2(3):185–9. doi:10.4161/isl.2.3.11654.CrossRefPubMed

12.

Lewis EC, Mizrahi M, Toledano M, Defelice N, Wright JL, Churg A, et al. Alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci USA. 2008;105(42):16236–41. doi:10.1073/pnas.0807627105.CrossRefPubMedCentralPubMed

13.

Wanner A, Arce AD, Pardee E. Novel therapeutic uses of alpha-1 antitrypsin: a window to the future. COPD. 2012;9(6):583–8. doi:10.3109/15412555.2012.717125.CrossRefPubMed

14.

Shahaf G, Moser H, Ozeri E, Mizrahi M, Abecassis A, Lewis EC. Alpha-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection. Mol Med. 2011;17(9–10):1000–11. doi:10.2119/molmed.2011.00145.PubMedCentralPubMed

15.

Lu Y, Parker M, Pileggi A, Zhang B, Choi YK, Molano RD, et al. Human alpha 1-antitrypsin therapy induces fatal anaphylaxis in non-obese diabetic mice. Clin Exp Immunol. 2008;154(1):15–21. doi:10.1111/j.1365-2249.2008.03721.x.CrossRefPubMedCentralPubMed

16.

Ma H, Lu Y, Li H, Campbell-Thompson M, Parker M, Wasserfall C, et al. Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease. Diabetologia. 2010;53(10):2198–204. doi:10.1007/s00125-010-1829-2.CrossRefPubMed

17.

Ye J, Liao YT, Jian YQ, Zhang XD, Wei P, Qi H, et al. Alpha-1-antitrypsin for the improvement of autoimmunity and allograft rejection in beta cell transplantation. Immunol Lett. 2013;150(1–2):61–8. doi:10.1016/j.imlet.2013.01.009.CrossRefPubMed

18.

Wang Y, Yan HJ, Zhou SY, Wang YS, Qi H, Deng CY, et al. The immunoregulation effect of alpha 1-antitrypsin prolong beta-cell survival after transplantation. PLoS One. 2014;9(4):e94548. doi:10.1371/journal.pone.0094548.CrossRefPubMedCentralPubMed

19.

Li FR, Wang XG, Deng CY, Qi H, Ren LL, Zhou HX. Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells. Clin Exp Immunol. 2010;161(2):357–63. doi:10.1111/j.1365-2249.2010.04178.x.PubMedCentralPubMed

20.

Qi H, Liu JP, Deng CY, Zhou HX, Deng SP, Li FR. A role for anti-CD45RB monoclonal antibody treatment upon dendritic cells. Immunol Res. 2012;52(3):250–7. doi:10.1007/s12026-012-8336-0.CrossRefPubMed

21.

Deng CY, Qi H, Wang XG, Zhou HX, Deng SP, Li FR. Role of T and dendritic cells in mouse islet allografts treated with anti-CD45RB monoclonal antibodies. Transplant Proc. 2011;43(7):2721–7. doi:10.1016/j.transproceed.2011.05.049.CrossRefPubMed

22.

Fleixo-Lima G, Ventura H, Medini M, Bar L, Strauss P, Lewis EC. Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes. J Diabetes Sci Technol. 2014;8(6):1193–203. doi:10.1177/1932296814547096.CrossRefPubMed

23.

Lewis EC. Expanding the clinical indications for alpha(1)-antitrypsin therapy. Mol Med. 2012;18:957–70. doi:10.2119/molmed.2011.00196.CrossRefPubMedCentralPubMed

24.

Burke SJ, Lu D, Sparer TE, Karlstad MD, Collier JJ. Transcription of the gene encoding TNF-alpha is increased by IL-1beta in rat and human islets and beta-cell lines. Mol Immunol. 2014;62(1):54–62. doi:10.1016/j.molimm.2014.05.019.CrossRefPubMed

25.

Wachlin G, Augstein P, Schroder D, Kuttler B, Kloting I, Heinke P, et al. IL-1beta, IFN-gamma and TNF-alpha increase vulnerability of pancreatic beta cells to autoimmune destruction. J Autoimmun. 2003;20(4):303–12.CrossRefPubMed

26.

Koulmanda M, Bhasin M, Awdeh Z, Qipo A, Fan Z, Hanidziar D, et al. The role of TNF-alpha in mice with type 1- and 2- diabetes. PLoS One. 2012;7(5):e33254. doi:10.1371/journal.pone.0033254.CrossRefPubMedCentralPubMed

27.

Gottlieb PA, Alkanani AK, Michels AW, Lewis EC, Shapiro L, Dinarello CA, et al. Alpha1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1beta responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. J Clin Endocrinol Metab. 2014;99(8):E1418–26. doi:10.1210/jc.2013-3864.CrossRefPubMed

28.

Abecassis A, Schuster R, Shahaf G, Ozeri E, Green R, Ochayon DE, et al. Alpha1-antitrypsin increases interleukin-1 receptor antagonist production during pancreatic islet graft transplantation. Cell Mol Immunol. 2014;11(4):377–86. doi:10.1038/cmi.2014.17.CrossRefPubMedCentralPubMed

29.

Pott GB, Chan ED, Dinarello CA, Shapiro L. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol. 2009;85(5):886–95. doi:10.1189/jlb.0208145.CrossRefPubMedCentralPubMed

30.

Geginat J, Paroni M, Maglie S, Alfen JS, Kastirr I, Gruarin P, et al. Plasticity of human CD4 T cell subsets. Front Immunol. 2014;5:630. doi:10.3389/fimmu.2014.00630.CrossRefPubMedCentralPubMed

31.

Suarez-Pinzon WL, Rabinovitch A. Approaches to type 1 diabetes prevention by intervention in cytokine immunoregulatory circuits. Int J Exp Diabetes Res. 2001;2(1):3–17.CrossRefPubMedCentralPubMed

32.

Kikodze N, Pantsulaia I, Rekhviashvili K, Iobadze M, Dzhakhutashvili N, Pantsulaia N, et al. Cytokines and T regulatory cells in the pathogenesis of type 1 diabetes. Georgian Med News. 2013;222:29–35.PubMed

33.

Sugimoto K, Itoh T, Takita M, Shimoda M, Chujo D, SoRelle JA, et al. Improving allogeneic islet transplantation by suppressing Th17 and enhancing Treg with histone deacetylase inhibitors. Transpl Int. 2014;27(4):408–15. doi:10.1111/tri.12265.CrossRefPubMed

34.

Bertin-Maghit S, Pang D, O’Sullivan B, Best S, Duggan E, Paul S, et al. Interleukin-1beta produced in response to islet autoantigen presentation differentiates T-helper 17 cells at the expense of regulatory T-cells: implications for the timing of tolerizing immunotherapy. Diabetes. 2011;60(1):248–57. doi:10.2337/db10-0104.CrossRefPubMedCentralPubMed

35.

Subramanian S, Shahaf G, Ozeri E, Miller LM, Vandenbark AA, Lewis EC, et al. Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+ FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metab Brain Dis. 2011;26(2):107–13. doi:10.1007/s11011-011-9239-9.CrossRefPubMed

36.

Lee CN, Lew AM, Wu L. The potential role of dendritic cells in the therapy of Type 1 diabetes. Immunotherapy. 2013;5(6):591–606. doi:10.2217/imt.13.48.CrossRefPubMed

37.

Thomas DC, Wong FS, Zaccone P, Green EA, Wallberg M. Protection of islet grafts through transforming growth factor-beta-induced tolerogenic dendritic cells. Diabetes. 2013;62(9):3132–42. doi:10.2337/db12-1740.CrossRefPubMedCentralPubMed

38.

Chen L, Qiu M, He W, Huang A, Liu J. Functional study of immature dendritic cells co-transfected with IL-10 and TGF-beta 1 genes in vitro. Mol Biol Rep. 2012;39(6):6633–9. doi:10.1007/s11033-012-1468-4.CrossRefPubMed

39.

Ozeri E, Mizrahi M, Shahaf G, Lewis EC. Alpha-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J Immunol. 2012;189(1):146–53. doi:10.4049/jimmunol.1101340.CrossRefPubMed

40.

Guttman O, Yossef R, Freixo-Lima G, Rider P, Porgador A, Lewis EC. Alpha1-Antitrypsin modifies general NK cell interactions with dendritic cells and specific interactions with islet beta-cells in favor of protection from autoimmune diabetes. Immunology. 2014;. doi:10.1111/imm.12403.PubMed

Titel: Immune protective effect of human alpha-1-antitrypsin gene during β cell transplantation in diabetic mice
verfasst von: Lu Yang
Yu-Ting Liao
Xiao-Fei Yang
Li-Wei Reng
Hui Qi
Fu-Rong Li
Publikationsdatum: 01.05.2015
Verlag: Springer US
Erschienen in: Immunologic Research / Ausgabe 1/2015
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-015-8636-2

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Immune protective effect of human alpha-1-antitrypsin gene during β cell transplantation in diabetic mice

Abstract

Neu im Fachgebiet HNO

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Predicting peptide vaccine candidates against H1N1 influenza virus through theoretical approaches

Involvement of ATF3 in the negative regulation of iNOS expression and NO production in activated macrophages

Erratum to: Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis

Participation of T cell immunoglobulin and mucin domain-3 (TIM-3) and its ligand (galectin-9) in the pathogenesis of active generalized vitiligo

A novel CD40LG deletion causes the hyper-IgM syndrome with normal CD40L expression in a 6-month-old child

Safety and efficacy study of lung cancer stem cell vaccine

Neu im Fachgebiet HNO

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

Update HNO